[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.163.129.96. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Comment & Response
January 19, 2016

Finerenone for Albuminuria in Patients With Diabetic Nephropathy

Author Affiliations
  • 1Division of Nephrology, West China Hospital of Sichuan University, Chengdu, Sichuan, China
JAMA. 2016;315(3):305-306. doi:10.1001/jama.2015.15996

To the Editor Dr Bakris and colleagues1 evaluated the safety and efficacy of dual blockade of the renin-angiotensin-aldosterone system by adding the nonsteroidal mineralocorticoid receptor antagonist (MRA) finerenone to an angiotensin-converting enzyme (ACE) inhibitor or an angiotensin receptor blocker in patients with diabetic nephropathy. The authors stated that the addition of finerenone resulted in improvement in the urinary albumin-creatinine ratio (UACR) compared with placebo. We have a number of concerns about the study.

First Page Preview View Large
First page PDF preview
First page PDF preview
×